Market pricing and medical insurance status of tepotinib in 2024

Tepotinib (Tepotinib), as a drug targeting MET exon 14 skipping mutations in metastatic non-small cell lung cancer Targeted therapeutic drugs for cell lung cancer (NSCLC), their mechanism of action is to block the MET signaling pathway, thereby curbing the growth and spread of tumors.

In 2024, tepotinib has not yet been covered by my country’s medical insurance system. Therefore, if patients choose this drug, they need to bear the cost themselves. The current market price is about more than 30,000 yuan. However, please note that the actual price may fluctuate depending on the location, medical institution and drug purchase channel. To ensure the accuracy of the information, patients are advised to conduct detailed consultation with their local medical institution or pharmacy before purchasing.

At the same time, compared with domestic original drugs, the price of foreign generic drugs of tepotinib appears to be more affordable. For example, the price of generic drugs in Laos is about more than 9,000 yuan. These generic drugs are highly similar to the original drugs in terms of drug ingredients, so their efficacy and safety are also similar.

Although the price of domestic original tepotinib is relatively high, patients can still consider choosing more reasonably priced foreign generic drugs as a treatment option. Of course, before choosing any drug, patients should first communicate with their doctor and consider the cost and efficacy of the drug to formulate a treatment strategy that best suits them. In addition, medical insurance policies and drug prices may be adjusted over time, and patients need to pay close attention to them in order to obtain the latest information and preferential policies in a timely manner.